home / stock / cing / cing news

CING News and Press, Cingulate Inc. From 04/04/23

Stock Information
Company Name: Cingulate Inc.
Stock Symbol: CING
Market: NASDAQ
Website: cingulate.com
Menu
CING CING Quote CING Short CING News CING Articles CING Message Board
Get CING Alerts

News, Short Squeeze, Breakout and More Instantly...
CING - Cingulate Completes First Cohort of Phase 3 Adult Onset and Duration Trial of CTx-1301 (dexmethylphenidate) for ADHD

Trial On Track for 3Q 2023 Results Pivotal Phase 3 Trial in Pediatric/Adolescent Patients Planned to Begin Mid-2023 KANSAS CITY, Kan., April 04, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) , a biopharmaceutical company utilizing its proprietary Precision Tim...
CING - AU, MVST and PALI are among pre market gainers

2023-03-30 08:44:07 ET SCYNEXIS ( SCYX ) +93% jumps 92% on licensing deal with GSK for anti-fungal agent. Freight Technologies ( FRGT ) +23% warded Whirlpool Contract. Cazoo Group ( CZOO ) +19% FY earnings call release Altus Power ( AMPS ) +...

CING - United Airlines, GitLab, TAL Education among premarket losers' pack

2023-03-14 08:34:23 ET GitLab ( GTLB ) -30% on Q4 earnings release . Cingulate ( CING ) -11% . 9 Meters Biopharma ( NMTR ) -9% after proposes to raise $5M in stock offering . BigBear.ai ( BBAI ) -9% on Q4 earnings release . B...

CING - HUT, NMTR and BYSI among mid-day movers

2023-03-13 12:54:16 ET Gainers: Provention ( PRVB ) +258% . Euda Health ( EUDA ) +41% . Calliditas ( CALT ) +31% . Cipher Mining ( CIFR ) +29% . Caleminder ( CMND ) +26% . Bakkt ( BKKT ) +26% . Hut 8 Mining ( HU...
CING - Provention, Caleminder top healthcare gainers; Cingulate, iCAD among losers

2023-03-13 10:02:38 ET Gainers: Provention Bio PRVB +248% . Caleminder ( CMND ) +38% . Calliditas Therapeutics ( CALT ) +32% . Euda Health ( EUDA ) +22% . Seagen  ( SGEN ) +15% . Losers: Cingulate CING -28...

CING - Cingulate stock slumps ~15% on commercialization pact for ADHD drug CTx-1301

2023-03-13 09:14:08 ET Cingulate ( NASDAQ: CING ) signed a joint commercialization agreement with Indegene for its lead drug candidate CTx-1301 to treat attention deficit/hyperactivity disorder (ADHD). Cingulate said the agreement spans cross-functional services via a...

CING - The Charles Schwab, Banco Santander, First Republic among major financials premarket losers' pack

2023-03-13 08:57:19 ET First Republic FRC -64% amid woes regarding SVB, Signature collapse . Western Alliance WAL -54% amid woes regarding SVB, Signature collapse . PacWest PACW -40% amid woes regarding SVB, Signature collapse . Euda Health ( EUDA...
CING - Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301

Go-to-Market Solution Provides Full Commercial Support for the First, True Entire Active-Day Medication Designed to treat ADHD Indegene Model Geared for Efficient National Commercial Launch in Multibillion-Dollar ADHD Market KANSAS CITY, Kan. and PRINCETON, N.J., March 13, 2023 (G...

CING - Cingulate GAAP EPS of -$0.41 misses by $0.04

2023-03-10 16:36:27 ET Cingulate press release ( NASDAQ: CING ): Q4 GAAP EPS of -$0.41 misses by $0.04 . As of December 31, 2022, Cingulate had $5.4 million in cash and cash equivalents, as compared to $16.5 million in cash and cash equivalents as of December 31, 2021....

CING - Cingulate Inc. Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical and Business Update

CTx-1301 Phase 3 Adult Dose-Optimization Study Ongoing; Results Expected 3Q 2023 Positive Top-Line Data from CTx-1301 Fed/Fast Study Announced, Full Results Submitted for Presentation at Forthcoming Medical Meeting CTx-1301 Pivotal Phase 3 Trial in Pediatric/Adolescent Patients ...
Previous 10 Next 10